Patents Assigned to Almirall, S.A.
  • Pharmaceutical compositions comprising dimethyl fumarate
    Patent number: 11602515
    Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastroresistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 14, 2023
    Assignee: Almirall, S.A.
    Inventor: Jorge Aubets Mir
  • COMPOSITIONS COMPRISING TIMOLOL AND THEIR USE IN THE TREATMENT OF ROSACEA BY TOPICAL ADMINISTRATION
    Publication number: 20210220368
    Abstract: The present invention relates to the use of timolol in treating rosacea, and to pharmaceutical compositions comprising timolol.
    Type: Application
    Filed: June 15, 2017
    Publication date: July 22, 2021
    Applicant: Almirall, S.A.
    Inventors: Bernat Vidal Juan, Maria Victoria Revilla Sanchez, Gema Tarrason Encuentra
  • Dosage and formulation
    Patent number: 11000517
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: May 11, 2021
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors
    Patent number: 10759793
    Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 1, 2020
    Assignee: Almirall, S.A.
    Inventors: Cristina Esteve Trias, Joan Taltavull Moll, Jacob Gonzalez Rodriguez, Bernat Vidal Juan
  • Pharmaceutical Compositions Comprising Dimethyl Fumarate
    Publication number: 20200197348
    Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastroresistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
    Type: Application
    Filed: June 25, 2018
    Publication date: June 25, 2020
    Applicant: Almirall, S.A.
    Inventor: Jorge AUBETS MIR
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent number: 10588895
    Abstract: Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Combinations comprising MABA compounds and corticosteroids
    Patent number: 10456390
    Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: October 29, 2019
    Assignee: Almirall, S.A.
    Inventors: Monica Aparici Virgili, Marta Calbet Murtro, Montserrat Miralpeix Guell, Amadeu Gavalda Monedero, Carlos Puig Duran
  • COMPOSITIONS COMPRISING TIMOLOL AND AN ANTI-INFLAMMATORY AGENT
    Publication number: 20190231788
    Abstract: The present invention relates to combinations comprising timolol and a compound useful for the treatment of rosacea selected from ivermectin, metronidazole and praziquantel and to the use of these combinations in the topical treatment of rosacea.
    Type: Application
    Filed: June 15, 2017
    Publication date: August 1, 2019
    Applicant: Almirall, S.A.
    Inventors: Nuria Godessart Marina, Gema Tarrason Encuentra
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 10300072
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 28, 2019
    Assignee: Almirall, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Amino-substituted heterocyclic derivatives as sodium channel inhibitors
    Patent number: 10214509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 26, 2019
    Assignee: Almirall, S.A.
    Inventors: James Duffy, Mark Stuart Chambers, Alastair Rae, James Osborne, Isabelle Anne Lemasson, Michael Daniel Goldsmith, Andrew Sharpe, Silvia Fonquerna Pou
  • Aminoindazole derivatives as sodium channel inhibitors
    Patent number: 10173985
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav 1.7, to compositions containing said derivatives and processes for their preparation.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: January 8, 2019
    Assignee: Almirall, S.A.
    Inventors: Laia Sole Feu, Silvia Fonquerna Pou
  • Dosage and formulation
    Patent number: 10085974
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 2, 2018
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent number: 10034867
    Abstract: Provided is a powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 31, 2018
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Bicyclic derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 10005771
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 26, 2018
    Assignee: Almirall, S.A.
    Inventors: Carlos Puig Duran, Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quiñones
  • Topical pharmaceutical compositions
    Patent number: 9907807
    Abstract: Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: March 6, 2018
    Assignee: ALMIRALL, S.A.
    Inventors: Fritjof Evers, Henning Mallwitz, Ricarda Wessel, Christoph Willers
  • Cyclohexylamine derivatives having ?2 adrenergic agonist and M3 muscarinic antagonist activities
    Patent number: 9757383
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: September 12, 2017
    Assignee: Almirall, S.A.
    Inventors: Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • Aclidinium for use in improving the quality of sleep in respiratory patients
    Patent number: 9737520
    Abstract: The present disclosure provides aclidinium or any of its stereoisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 22, 2017
    Assignee: Almirall, S.A.
    Inventors: Maria Esther Garcia Gil, Gonzalo De Miquel Serra, Maria Jose Sala Peinado
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent number: 9687478
    Abstract: Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Type: Grant
    Filed: April 9, 2016
    Date of Patent: June 27, 2017
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Cyclohexylamine derivatives having ?2 adrenergic antagonist and M3 muscarinic antagonist activities
    Patent number: 9643961
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 9, 2017
    Assignee: Almirall, S.A.
    Inventors: Maria Prat Quinones, Silvia Fonquerna Pou, Carlos Puig Duran, Wenceslao Lumeras Amador, Jose Aiguade Bosch, Juan Francisco Caturla Javaloyes
  • Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
    Patent number: RE46417
    Abstract: A compound according to formula (I) wherein: © is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; which shows high affinity for muscarinic M3 receptors (Hm3).
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 30, 2017
    Assignee: Almirall, S.A.
    Inventors: Dolors Fernandez Forner, Maria Prat Quiñones, Maria Antonia Buil Albero